Opioid Class REMS: FDA Wants Prescriber/Pharmacist Certification
This article was originally published in The Pink Sheet Daily
Executive Summary
Public meeting set for end of May: next step on the difficult road to a class-wide REMS. Important precedent in the making.
You may also be interested in...
Neuromed's Extended Release Hydromorphone Gets Committee Review
Exalgo will be another test of FDA's willingness to approve opioids in the absence of a class-wide REMS.
Neuromed's Extended Release Hydromorphone Gets Committee Review
Exalgo will be another test of FDA's willingness to approve opioids in the absence of a class-wide REMS.
FDA Class-Wide REMS Meeting Won’t Deter Embeda Approval, King Believes
Drug maker expects to meet with FDA in July on “complete response” for Remoxy.